Dr Reddy's Labs gets EIR from USFDA for Srikakulam unit

Published On 2018-08-24 05:00 GMT   |   Update On 2018-08-24 05:00 GMT

New Delhi: Dr Reddy's Laboratories said it has received an Establishment Inspection Report (EIR) from the US health regulator for its Srikakulam facility in Andhra Pradesh.


The Srikakulam unit manufactures active pharmaceutical ingredients (APIs).


The EIR from the United States Food and Drug Administration (USFDA) indicates closure of the audit of the plant, Dr Reddy's Labs said in a BSE filing.


In an earlier filing on June 2, 2018, the company had said that the audit of the Srikakulam plant (SEZ) by USFDA had been completed with no observations.

Article Source : PTI

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News